双特异性T细胞衔接器治疗中房颤报告:FAERS不良事件分析
本研究基于FAERS数据库2014年第二季度至2024年12月31日的去重个体病例安全报告,分析双特异性T细胞衔接器(BiTE)治疗与房颤(AF)不成比例报告信号。共识别14,337例BiTE作为可疑药物的病例,其中97例(0.68%)报告AF,整体ROR为1.28(95%CI 1.04-1.57),IC为0.35(95%CI 0.02-0.60);epcoritamab和mosunetuzumab显示信号,其他BiTE未见。
要点
- BiTE治疗整体与AF报告呈不成比例信号(ROR 1.28,95%CI 1.04-1.57)。
- epcoritamab和mosunetuzumab与AF报告信号相关,其他BiTE未显示。
- 阳性对照CAR-T也显示AF信号,阴性对照对乙酰氨基酚未显示。
核心结论
- 在FAERS中,BiTE治疗与AF不成比例报告相关,该关联需进一步研究。
研究设计与样本
- 基于FAERS数据库2014年第二季度至2024年12月31日的去重个体病例安全报告,分析BiTE治疗与AF的不成比例报告信号。
- 共分析11,129,381份去重ICSRs,其中14,337例以BiTE为可疑药物。
主要发现
- 14,337例BiTE相关病例中97例(0.68%)报告AF。
- BiTE整体AF报告信号:ROR 1.28(95%CI 1.04-1.57),IC 0.35(95%CI 0.02-0.60)。
- epcoritamab的AF报告信号:ROR 2.95(95%CI 2.01-4.18),IC 1.50(95%CI 0.91-1.92)。
- mosunetuzumab的AF报告信号:ROR 3.88(95%CI 1.92-7.01),IC 1.76(95%CI 0.74-2.46)。
- CAR-T阳性对照显示AF信号:ROR 2.40(95%CI 2.05-2.79),IC 1.24(95%CI 0.99-1.42);对乙酰氨基酚阴性对照未显示信号。
临床怎么用
- 使用BiTE治疗(尤其epcoritamab或mosunetuzumab)时应加强AF监测与评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Bispecific T-cell engager (BiTE) therapies activate cytotoxic T cells and promote cytokine release, potentially increasing the risk of atrial fibrillation (AF). The atrial arrhythmic risk associated with BiTE therapy remains unclear. METHODS: We analyzed individual case safety reports (ICSRs) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from the second quarter of 2014 to December 31, 2024. Reporting odds ratios (RORs) with 95% CIs and information components (ICs) with 95% credible intervals (CrIs) were used to assess whether AF was disproportionally reported with BiTE therapy as compared to all other drugs in the FAERS. We also evaluated positive (chimeric antigen receptor T-cell [CAR-T] therapy) and negative (paracetamol) control therapies. RESULTS: Analysis of 11,129,381 deduplicated ICSRs identified 14,337 cases involving BiTE therapy as a suspect drug, with 97 (0.68%) reporting AF. A signal for disproportional reporting (SDR) of AF with BiTE therapies was observed (ROR, 1.28 [95% CI, 1.04-1.57]; IC, 0.35 [95% CrI, 0.02-0.60]). Individually, epcoritamab (ROR, 2.95 [95% CI, 2.01-4.18]; IC, 1.50 [95% CrI, 0.91-1.92]) and mosunetuzumab (ROR, 3.88 [95% CI, 1.92-7.01]; IC, 1.76 [95% CrI, 0.74-2.46]) were associated with SDRs. No other BiTE therapy showed an SDR. CAR-T therapy, the positive control, showed an SDR for AF (ROR, 2.40 [95% CI, 2.05-2.79]; IC, 1.24 [95% CrI, 0.99-1.42]). In contrast, the negative control, paracetamol, did not. CONCLUSION: AF appears to be disproportionally reported with BiTE therapy in the FAERS. This association warrants further investigation.
引用
- Portela B, Abdelghany O, Coleman CI, et al. Reporting of atrial fibrillation with bispecific T-cell engagers in the Food and Drug Administration Adverse Event Reporting System. Am J Health Syst Pharm. 2026. PMID: 42263195. doi:10.1093/ajhp/zxag168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。